Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Wants Matrix Reloaded – Announces Delisting Plans For $133 Million

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Mylan - the third-largest generic drug maker in the world - plans to de-list its Indian subsidiary Matrix Labs from the Indian stock exchanges at a cost of $133 million. The Pittsburgh-headquartered generic drug maker has approved an indicative acquisition price of up to 150 rupees ($3 per share), reflecting a premium of 27 percent of the closing share price of Matrix on March 26. Mylan will use current cash balances to fund the additional acquisition of Matrix shares

You may also be interested in...



India Market Bug Bites Mylan As It Sets Sights On Stage-Wise Product Rollouts

Following on the hefty deal struck last week between Abbott and Piramal Healthcare for the Indian firm's generics business, U.S. generics leader Mylan prepares to enter the Indian formulations market in a big way.

India Market Bug Bites Mylan As It Sets Sights On Stage-Wise Product Rollouts

Following on the hefty deal struck last week between Abbott and Piramal Healthcare for the Indian firm's generics business, U.S. generics leader Mylan prepares to enter the Indian formulations market in a big way.

After Abbott, India Market Bug Bites Mylan Too As It Sets Sights On Stage-wise Product Rollout

MUMBAI - The potential of the Indian pharmaceutical market to double from the present $8 billion to $15 billion in the next five years led Abbott last week to strike the most richly valued deal for Piramal Healthcare's generic drug businesses, but the action for a share of the Indian market is set to accelerate further as Mylan - the third largest generic company in the world and the largest in the U.S. with sales exceeding $5 billion - is preparing to enter the Indian formulations market

Related Content

UsernamePublicRestriction

Register

SC071185

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel